Earnings call transcripts

Management framed the quarter as broad-based ICL share gains despite weak refractive markets, with China recovered and U.S. launch investments still building adoption.

Management framed 2023 as a transition toward scale and profitability, with cost cuts, product launches and channel normalization underpinning second-half confidence.

Management framed recovery as U-shaped but contingent on SMB conditions and credit-enhancement negotiations, prioritizing asset quality and margin sustainability over near-term growth.

Management framed 2023 around strong GLP-1 demand and capacity expansion, while stressing supply limits and unusually high uncertainty around market growth.

Management framed 2023 as an investment year, with confidence in China’s recovery and a sharper push to build U.S. EVO adoption. $5 million of Q4 sales were removed amid China’s COVID-related disruption.

Management framed 2023 around maintaining earnings while repositioning the balance sheet and defining growth beyond the $10 billion Durbin limit.

Management framed 2022 as strong share-gain execution but reset costs and profitability timing after weaker European demand and channel caution.

Management framed performance as broad-based, with GLP-1 demand driving growth while supply constraints and declining insulin sales shaped the outlook. 40% of U.S.

Management framed the reset as temporary China demand deferral and currency pressure, while shifting resources toward EVO and signaling stronger U.S. momentum.

Management framed the quarter as share gains and execution against a softer European EV market, with near-term caution but confidence in long-term growth.

Management framed the quarter as a deliberate trade-off: protect credit quality now while preserving capacity to resume growth when conditions improve.

Management framed the raised outlook around accelerating GLP-1 demand, while emphasizing capacity expansion and continued investment to address supply constraints.